N-Acetylcysteine (NAC) Research
7 peer-reviewed studies supporting this intervention. Evidence rating: B
Study Comparison
| Study | Year | Type | Journal | Key Finding |
|---|---|---|---|---|
| Peng T et al. | 2024 | General hospital psychiatry | Updated meta-analysis of 12 studies (904 patients) found adjunctive NAC effectively reduces depressive symptoms, particularly in bipolar disorder, with optimal doses of 1,000-2,750 mg/day | |
| Eghdami S et al. | 2024 | Frontiers in psychiatry | Meta-analysis of 6 RCTs found NAC augmentation with SSRIs may benefit patients with moderate to severe OCD, showing improved Y-BOCS scores at 5-8 weeks | |
| Raghu G et al. | 2022 | Review | Hepatology Communications | NAC supports liver health through glutathione replenishment and has established medical uses for acetaminophen toxicity, with emerging evidence for other liver conditions. |
| Zheng W et al. | 2019 | Acta psychiatrica Scandinavica | Meta-analysis found NAC significantly improves symptoms across major mental disorders including schizophrenia, bipolar, and depression, supporting its role as a transdiagnostic psychiatric treatment | |
| Rushworth GF et al. | 2014 | Study | Pharmacology & Therapeutics | Review established NAC as the gold standard treatment for acetaminophen toxicity and explored its broader therapeutic potential through glutathione replenishment. |
| Dean O et al. | 2011 | Study | Journal of Psychiatry & Neuroscience | Comprehensive review established NAC's potential therapeutic role across multiple psychiatric conditions through glutathione replenishment, glutamate modulation, and anti-inflammatory effects. |
| Berk M et al. | 2009 | Study | Biological Psychiatry | NAC supplementation improved symptoms in schizophrenia patients, supporting its role in psychiatric conditions involving oxidative stress and glutathione deficiency. |
Study Details
General hospital psychiatry
View Summary
This updated systematic review and meta-analysis evaluated NAC for depression in patients with psychiatric disorders including bipolar disorder and major depressive disorder. Twelve studies with 904 patients were included, with daily NAC doses ranging from 1,000 to 3,000 mg. Adjunctive NAC was found to effectively ameliorate depressive symptoms, particularly in bipolar disorder.
Frontiers in psychiatry
View Summary
This systematic review and meta-analysis investigated NAC as a glutamate-modulating augmentation agent for moderate to severe OCD. Six RCTs with 195 patients were included. NAC augmentation with SSRIs showed positive outcomes on total Y-BOCS scores when used for 5-8 weeks.
Hepatology Communications
View Summary
This comprehensive review examined the mechanisms and clinical applications of N-acetylcysteine (NAC) in liver diseases.
Mechanisms of action:
- Precursor to glutathione (master antioxidant)
- Direct antioxidant effects
- Anti-inflammatory properties
- Supports Phase II liver detoxification
Established uses:
- Acetaminophen overdose (standard treatment)
- IV NAC highly effective if given early
- Prevents liver failure from toxicity
- Life-saving in acute poisoning
Emerging applications:
| Condition | Evidence | Findings |
|---|---|---|
| Non-alcoholic fatty liver | Moderate | Improved enzymes, steatosis |
| Alcoholic liver disease | Low-Moderate | Some benefit |
| Acute liver failure | Moderate | Improved outcomes |
| Drug-induced liver injury | Low | Case reports positive |
Glutathione connection:
- NAC rapidly converts to cysteine
- Cysteine is rate-limiting for glutathione
- Glutathione is liver's primary antioxidant
- Depleted in many liver conditions
Dosing in studies:
- Oral: 600-1800 mg daily
- IV: Higher doses for acute toxicity
- Generally well-absorbed orally
- Split dosing may be better tolerated
Safety profile:
- Generally well-tolerated
- GI upset most common side effect
- Nausea with high doses
- Rare allergic reactions
Clinical significance:
Establishes NAC as a well-researched option for liver support through glutathione pathway, with strong evidence for acute uses and growing evidence for chronic liver support.
Acta psychiatrica Scandinavica
View Summary
This systematic review and meta-analysis evaluated NAC for major mental disorders across multiple diagnostic categories. The study found NAC significantly improved various psychiatric symptoms, supporting its potential as a broad-spectrum treatment adjunct in psychiatry. The glutathione precursor mechanism may explain transdiagnostic benefits through oxidative stress reduction.
Pharmacology & Therapeutics
View Summary
Comprehensive review of NAC's mechanisms and therapeutic applications, from established to emerging uses.
Journal of Psychiatry & Neuroscience
View Summary
Review of NAC's mechanisms and clinical evidence in psychiatric disorders.
Biological Psychiatry
View Summary
Landmark RCT examining NAC supplementation for schizophrenia, establishing its potential in psychiatric applications.
Evidence Assessment
This intervention has moderate evidence from some randomized trials and consistent observational data, though more research would strengthen conclusions.